In terms of Regulation 30 read with Para A of Part A of Schedule III to SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries Ltd (BSE: 543828) submitted an updated investor presentation covering FY25 and H2FY25 results. FY25 revenue rose 9% YoY to Rs 505 Cr, while EBITDA jumped 75% to Rs 39.9 Cr with margin expanding from 4.9% to 7.9%. PAT grew 39.3% to Rs 16 Cr with margin improving to 3.2%. The company highlighted margin optimization focus through higher exports, manufacturing sales, and better API resale margins. Key strategic updates include a MoU with Ardes Laboratories for a CDMO project, a new R&D centre in Dehradun, PLI scheme approval for Vitamin B1/B6 manufacturing (Rs 86.7 Cr committed investment), a new Palghar manufacturing unit, and a 40% PSI-2019 subsidy for its Mahad project. Subsidiary Ratna Lifesciences was turned around from losses to Rs 7.1 Cr profit in FY25.
Strong margin expansion and improving profitability signal operational leverage, which is positive for shareholders. However, working capital remains stretched (inventory days at 116) and current borrowings surged to Rs 160.3 Cr from Rs 94.3 Cr, which warrants monitoring.